CycloLab picks up the gauntlet to fight coronavirus
The novel coronavirus SARS-CoV-2 is affecting 65 countries and territories around the world with almost 90,000 reported cases and almost
Author: Tamas Sohajda
Cyclolab R&D Director
Gilead Sciences Initiates Two Phase 3 Studies of Investigational SBECD-enabled Antiviral Remdesivir for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of
iFLUX launches cyclodextrin-based PFAS cartridge to monitor mobility of PFAS groundwater plumes
Much has already been written about PFAS. But when it comes to the behavior of PFAS in groundwater, there’s less
The role of Roquette’s KLEPTOSE® HPbCD in the fight against coronavirus
Roquette has recently identified that its KLEPTOSE® hydroxypropyl beta-cyclodextrins (HPβCD) product, a functional excipient and a specialty active pharmaceutical ingredient (API),
Cyclo Therapeutics Presents Clinical Trial Data on Niemann-Pick Type C Disease
Cyclo Therapeutics, Inc. a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C (NPC)
Gilead uses SBECD-enabled remdesivir (GS-5734) for treating the first case of the 2019 novel coronavirus in the United States
Gilead Sciences’ SBECD-enabled remdesivir (GS-5734) was highlighted in the New England Journal of Medicine last week for treating the first
Marinus Data from SBECD-enabled Ganaxolone Phase 2 Trial in Refractory Status Epilepticus
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Underdog Launches With $4M to Target “Toxic” Form of Cholesterol
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in
Technical training on cyclodextrin formulations – survey
Dear Colleagues, According to recent communications with some of our partners, we believe that there is potential interest in hosting
Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol
Ligand Pharmaceuticals Incorporated presented positive results from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN